Breast Cancer Connect
  • Saved

Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib - PubMed

Genomic Profiling of Premenopausal HR+ and HER2- Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34504990/

In this study-to our knowledge, the first large study of premenopausal patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer-multiple genomic alterations were associated with...

  • Saved

Treatment Patterns And Outcomes Of Women With Symptomatic And Asymptomatic Breast Cancer Brain Metastases: A Single-Centre Retrospective Study - PubMed

Treatment Patterns And Outcomes Of Women With Symptomatic And Asymptomatic Breast Cancer Brain Metastases: A Single-Centre Retrospective Study - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34506676/

Although triple negative and HER2+ breast cancer have a predilection for metastasis to the central nervous system (CNS), patients with hormone receptor (HR)+/HER2- breast cancer represent a high proportion of...

  • Saved

De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? - PubMed

De-escalation of Endocrine Therapy in Early Hormone Receptor-positive Breast Cancer: When Is Local Treatment Enough? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34506321/

1 Department of Surgery, University of Texas Medical Branch, Galveston, Texas. 2 Department of Preventive Medicine and Population Health, Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas. 3...

  • Saved

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - PubMed

Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34450552/

1 Department of Medicine II, Hematology & Oncology, University of Frankfurt, Germany. 2 Gynecologic Oncology Practice, Hannover, Germany. 3 Oncological Practice Neumarkt, Germany. 4 MediOnko-Institute GbR, Berlin, Germany. 5 Department...

  • Saved

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer - PubMed

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34481367/

doi: 10.1016/j.breast.2021.08.016. Online ahead of print. 1 Davidoff Cancer Center, Institute of Oncology, Rabin Medical Center, Petah Tikva, Israel. 2 Davidoff Cancer Center, Institute of Oncology, Rabin Medical Center, Petah...

  • 4yr
    Key Points • Conclusion/Relevance: “The prognostic impact of HER2-low expression in early-stage luminal disease varies across the genomic risk, with significant favorable outcomes of HER2-low expression compared to HER2-0 in women Show More